| scholarly article | Q13442814 |
| P50 | author | M.Reza Jabalameli | Q64877942 |
| P2093 | author name string | Benjamin Bell | |
| Saeid Charsouei | |||
| Amin Karimi-Moghadam | |||
| P2860 | cites work | PINK1 is selectively stabilized on impaired mitochondria to activate Parkin | Q21145802 |
| Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa | Q82213842 | ||
| Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: effect of in vitro differentiation on graft survival and teratoma formation | Q82927480 | ||
| R632W mutation in PLA2G6 segregates with dystonia-parkinsonism in a consanguineous Iranian family | Q82990460 | ||
| Toward a redefinition of Parkinson's disease | Q83264509 | ||
| Etiology and pathogenesis of Parkinson's disease | Q84231134 | ||
| Serum Vitamins and Heavy Metals in Blood and Urine, and the Correlations among Them in Parkinson’s Disease Patients in China | Q84372097 | ||
| Summary of GIGYF2 studies in Parkinson's disease: the burden of proof | Q84885754 | ||
| Young-onset parkinsonism due to homozygous duplication of α-synuclein in a consanguineous family | Q95814006 | ||
| A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism | Q21560999 | ||
| Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain | Q21563315 | ||
| Parkinson's disease-associated kinase PINK1 regulates Miro protein level and axonal transport of mitochondria | Q21563375 | ||
| Parkinson's disease: clinical features and diagnosis | Q22242021 | ||
| Parkinson's disease: from monogenic forms to genetic susceptibility factors | Q22242870 | ||
| A review of Parkinson's disease | Q22242927 | ||
| Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update | Q22252904 | ||
| Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase | Q22254584 | ||
| A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death | Q24291746 | ||
| Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65 | Q24292901 | ||
| LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation | Q24294635 | ||
| Ubiquitin is phosphorylated by PINK1 to activate parkin | Q24296532 | ||
| Ataxin-2 and its Drosophila homolog, ATX2, physically assemble with polyribosomes | Q24296835 | ||
| topors, a p53 and topoisomerase I-binding RING finger protein, is a coactivator of p53 in growth suppression induced by DNA damage | Q24296904 | ||
| PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility | Q24296955 | ||
| Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation | Q24297033 | ||
| PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1 | Q24297155 | ||
| The mitochondrial intramembrane protease PARL cleaves human Pink1 to regulate Pink1 trafficking | Q24297960 | ||
| The Parkinson's disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis | Q24298775 | ||
| Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy | Q24300975 | ||
| LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1 | Q24301357 | ||
| The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease | Q24301425 | ||
| Mitochondrial outer-membrane protein FUNDC1 mediates hypoxia-induced mitophagy in mammalian cells | Q24302858 | ||
| Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis | Q24304952 | ||
| DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2 | Q24305442 | ||
| Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress | Q28592727 | ||
| GIGYF2 gene disruption in mice results in neurodegeneration and altered insulin-like growth factor signaling | Q28593816 | ||
| Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development | Q28594513 | ||
| DNAJC13 mutations in Parkinson disease | Q28658355 | ||
| Parametric and nonparametric linkage analysis: a unified multipoint approach | Q28762162 | ||
| Probes of ubiquitin E3 ligases enable systematic dissection of parkin activation | Q28830194 | ||
| Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy | Q29147504 | ||
| Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database | Q29417106 | ||
| Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway | Q29547371 | ||
| Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results | Q29547377 | ||
| Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy | Q29614178 | ||
| Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease | Q29614900 | ||
| Epidemiology of Parkinson's disease | Q29614901 | ||
| Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study | Q29614953 | ||
| Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization | Q29615622 | ||
| Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL | Q29615624 | ||
| The PINK1/Parkin pathway regulates mitochondrial morphology | Q29615641 | ||
| Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin | Q29615684 | ||
| Association between early-onset Parkinson's disease and mutations in the parkin gene | Q29615733 | ||
| PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy | Q29616005 | ||
| PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity | Q29617292 | ||
| Eaten alive: a history of macroautophagy | Q29617841 | ||
| PINK1-dependent recruitment of Parkin to mitochondria in mitophagy | Q29620567 | ||
| PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65 | Q29622844 | ||
| An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. | Q30350674 | ||
| Lack of replication of association between GIGYF2 variants and Parkinson disease. | Q30437358 | ||
| PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study | Q30448742 | ||
| Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London | Q30490116 | ||
| Mutation in VPS35 associated with Parkinson's disease impairs WASH complex association and inhibits autophagy | Q30578370 | ||
| Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice | Q30764264 | ||
| Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases | Q33235503 | ||
| Meta-analysis in genome-wide association datasets: strategies and application in Parkinson disease | Q33276409 | ||
| The mitochondrial fusion-promoting factor mitofusin is a substrate of the PINK1/parkin pathway | Q33552320 | ||
| LRRK2 mutations and risk variants in Japanese patients with Parkinson's disease | Q33682480 | ||
| ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies | Q33715666 | ||
| Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease | Q33723751 | ||
| Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS | Q33894621 | ||
| Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration | Q33991769 | ||
| Manganese and Parkinson's disease: a critical review and new findings | Q34060040 | ||
| SCA2 may present as levodopa-responsive parkinsonism | Q34187852 | ||
| Two novel proteins that are linked to insulin-like growth factor (IGF-I) receptors by the Grb10 adapter and modulate IGF-I signaling | Q28505191 | ||
| Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice | Q28507648 | ||
| alpha-Synuclein produces a long-lasting increase in neurotransmitter release | Q28510893 | ||
| Vps26A and Vps26B subunits define distinct retromer complexes | Q28586140 | ||
| Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron | Q28589324 | ||
| PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria | Q28592217 | ||
| Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies | Q24307627 | ||
| Oxygen-dependent expression of cytochrome c oxidase subunit 4-2 gene expression is mediated by transcription factors RBPJ, CXXC5 and CHCHD2 | Q24307974 | ||
| Oxidative status of DJ-1-dependent activation of dopamine synthesis through interaction of tyrosine hydroxylase and 4-dihydroxy-L-phenylalanine (L-DOPA) decarboxylase with DJ-1 | Q24309004 | ||
| Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily | Q24310218 | ||
| DJ-1 induces thioredoxin 1 expression through the Nrf2 pathway | Q24312506 | ||
| The Parkinson's disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy | Q24316726 | ||
| Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism | Q24321359 | ||
| Mitochondrial localization of DJ-1 leads to enhanced neuroprotection | Q24324226 | ||
| Hereditary early-onset Parkinson's disease caused by mutations in PINK1 | Q24337084 | ||
| Nuclear translocation of DJ-1 during oxidative stress-induced neuronal cell death | Q24337858 | ||
| DJ-1 transcriptionally up-regulates the human tyrosine hydroxylase by inhibiting the sumoylation of pyrimidine tract-binding protein-associated splicing factor | Q24338249 | ||
| p53: 25 years after its discovery | Q24338379 | ||
| Broad activation of the ubiquitin–proteasome system by Parkin is critical for mitophagy | Q24339224 | ||
| Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies | Q24606055 | ||
| Genome-wide association study reveals genetic risk underlying Parkinson's disease | Q24646654 | ||
| Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease | Q24656075 | ||
| Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates caspase activity in apoptosis | Q24672350 | ||
| The Grb10/Nedd4 complex regulates ligand-induced ubiquitination and stability of the insulin-like growth factor I receptor | Q24682781 | ||
| Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES- derived cell model of primary Parkinsonism | Q24797276 | ||
| Linking F-box protein 7 and parkin to neuronal degeneration in Parkinson's disease (PD) | Q26752685 | ||
| Reactive oxygen species: from health to disease | Q26864075 | ||
| Molecular mechanisms of presynaptic membrane retrieval and synaptic vesicle reformation | Q27003165 | ||
| Morphological control of mitochondrial bioenergetics | Q27006036 | ||
| Chaperone-mediated autophagy: roles in neurodegeneration | Q27016100 | ||
| Genetic linkage analysis in the age of whole-genome sequencing | Q27027718 | ||
| Mechanisms of mitophagy | Q27310261 | ||
| Progressive Axonal Degeneration of Nigrostriatal Dopaminergic Neurons in Calcium-Independent Phospholipase A2β Knockout Mice | Q27313281 | ||
| dAtaxin-2 mediates expanded Ataxin-1-induced neurodegeneration in a Drosophila model of SCA1 | Q27314605 | ||
| PINK1-Parkin pathway activity is regulated by degradation of PINK1 in the mitochondrial matrix | Q27316288 | ||
| The Sac1 domain of SYNJ1 identified mutated in a family with early-onset progressive Parkinsonism with generalized seizures | Q37215037 | ||
| Beyond ubiquitination: the atypical functions of Fbxo7 and other F-box proteins. | Q37272000 | ||
| Neurobiology and treatment of Parkinson's disease | Q37337617 | ||
| Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations | Q37361830 | ||
| Mutations in Fis1 disrupt orderly disposal of defective mitochondria | Q37416492 | ||
| The genetics of Parkinson's syndromes: a critical review | Q37472412 | ||
| Pathogenic variants in HTRA2 cause an early-onset mitochondrial syndrome associated with 3-methylglutaconic aciduria. | Q37547480 | ||
| Mitochondrial Rab GAPs govern autophagosome biogenesis during mitophagy | Q37594853 | ||
| Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria | Q37631959 | ||
| PINK1 function in health and disease | Q37668218 | ||
| Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations | Q37776461 | ||
| α-Synuclein in Parkinson's disease | Q37987146 | ||
| Programmed cell death in Parkinson's disease | Q38036233 | ||
| Lysosome-dependent pathways as a unifying theme in Parkinson's disease. | Q38038561 | ||
| Mitochondrial dynamics in neurodegeneration | Q38060435 | ||
| α-Synuclein and mitochondrial dysfunction in Parkinson's disease | Q38077665 | ||
| Neuromelanin of the human substantia nigra: an update | Q38155132 | ||
| Protective and toxic roles of dopamine in Parkinson's disease | Q38189127 | ||
| Genetics and genomics of Parkinson's disease | Q38233866 | ||
| Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. | Q38363823 | ||
| Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease | Q38372209 | ||
| The Parkinson Disease Mitochondrial Hypothesis: Where Are We at? | Q38374332 | ||
| Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study | Q38429187 | ||
| BCL2L13 is a mammalian homolog of the yeast mitophagy receptor Atg32 | Q38617489 | ||
| Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies | Q38712646 | ||
| The mitochondrial protein BNIP3L is the substrate of PARK2 and mediates mitophagy in PINK1/PARK2 pathway | Q38917518 | ||
| The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer | Q39072935 | ||
| Stimulation of vesicular monoamine transporter 2 activity by DJ-1 in SH-SY5Y cells | Q39354267 | ||
| RNA-binding disturbances as a continuum from spinocerebellar ataxia type 2 to Parkinson disease | Q39356825 | ||
| Dopaminergic neurons derived from human induced pluripotent stem cells survive and integrate into 6-OHDA-lesioned rats | Q39788084 | ||
| Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. | Q39838070 | ||
| Sumoylation is critical for DJ-1 to repress p53 transcriptional activity. | Q40002714 | ||
| DJ-1 decreases Bax expression through repressing p53 transcriptional activity | Q40043929 | ||
| Inhibition of tyrosine hydroxylase expression in alpha-synuclein-transfected dopaminergic neuronal cells | Q40526144 | ||
| Loss of FBXO7 (PARK15) results in reduced proteasome activity and models a parkinsonism-like phenotype in mice | Q41730755 | ||
| A dimeric PINK1-containing complex on depolarized mitochondria stimulates Parkin recruitment. | Q41846746 | ||
| Loss of PINK1 enhances neurodegeneration in a mouse model of Parkinson's disease triggered by mitochondrial stress. | Q41846921 | ||
| Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models | Q41871999 | ||
| Deficiency of HTRA2/Omi is associated with infantile neurodegeneration and 3-methylglutaconic aciduria. | Q41924560 | ||
| ParkDB: a Parkinson's disease gene expression database | Q42183671 | ||
| Dopaminergic neuronal dysfunction associated with parkinsonism in both a Gaucher disease patient and a carrier | Q42505823 | ||
| Progressive loss of striatal neurons causes motor dysfunction in MND2 mutant mice and is not prevented by Bcl-2. | Q42521333 | ||
| The adapter protein GRB10 is an endogenous negative regulator of insulin-like growth factor signaling | Q42812036 | ||
| Negative regulation of insulin-stimulated mitogen-activated protein kinase signaling by Grb10. | Q42834104 | ||
| Identification of a novel Zn2+-binding domain in the autosomal recessive juvenile Parkinson-related E3 ligase parkin. | Q43123357 | ||
| Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese | Q43864807 | ||
| Case-control study of environmental risk factors for Parkinson's disease in Belgium | Q44174971 | ||
| Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons | Q44258606 | ||
| Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants | Q44410269 | ||
| Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study | Q44499883 | ||
| The PLA2G6 gene in early‐onset Parkinson's disease | Q44642015 | ||
| Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells | Q44842227 | ||
| Meg1/Grb10 overexpression causes postnatal growth retardation and insulin resistance via negative modulation of the IGF1R and IR cascades. | Q45308583 | ||
| DNAJC6 is responsible for juvenile parkinsonism with phenotypic variability. | Q45493890 | ||
| rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease | Q45870012 | ||
| SNCA locus duplication carriers: from genetics to Parkinson disease phenotypes. | Q45941471 | ||
| Genetic variability in the mitochondrial serine protease HTRA2 contributes to risk for Parkinson disease | Q46233748 | ||
| Parkinson Sac Domain Mutation in Synaptojanin 1 Impairs Clathrin Uncoating at Synapses and Triggers Dystrophic Changes in Dopaminergic Axons | Q46358347 | ||
| Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms | Q46583182 | ||
| DJ-1 mutations and parkinsonism-dementia-amyotrophic lateral sclerosis complex. | Q46766700 | ||
| MNRR1 (formerly CHCHD2) is a bi-organellar regulator of mitochondrial metabolism | Q46825348 | ||
| VPS35 dysfunction impairs lysosomal degradation of α-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease. | Q46854670 | ||
| Parkinson's disease-linked DNAJC13 mutation aggravates alpha-synuclein-induced neurotoxicity through perturbation of endosomal trafficking | Q47224887 | ||
| The parkinsonian phenotype of spinocerebellar ataxia type 2. | Q47254835 | ||
| GIGYF2 mutations are not a frequent cause of familial Parkinson's disease | Q47688721 | ||
| GIGYF2 Asn56Ser and Asn457Thr mutations in Parkinson disease patients | Q47839456 | ||
| Analysis of DNAJC13 mutations in French-Canadian/French cohort of Parkinson's disease | Q47852184 | ||
| The ubiquitin pathway in Parkinson's disease | Q48015939 | ||
| The Parkinson disease-related protein DJ-1 counteracts mitochondrial impairment induced by the tumour suppressor protein p53 by enhancing endoplasmic reticulum-mitochondria tethering | Q48158987 | ||
| VPS13C-Another Hint at Mitochondrial Dysfunction in Familial Parkinson's Disease | Q48225611 | ||
| Parkin mutations are frequent in patients with isolated early-onset parkinsonism | Q48245134 | ||
| DNAJC13 genetic variants in parkinsonism. | Q48457194 | ||
| Structure and Function of Fbxo7/PARK15 in Parkinson's Disease. | Q48510456 | ||
| Clinical, positron emission tomography, and pathological studies of DNAJC13 p.N855S Parkinsonism | Q48565662 | ||
| Frequency of the D620N mutation in VPS35 in Parkinson disease | Q50254806 | ||
| PARK20 caused by SYNJ1 homozygous Arg258Gln mutation in a new Italian family | Q50471729 | ||
| Complex phenotypes in an Indian family with homozygous SCA2 mutations | Q51944358 | ||
| Neuroaxonal dystrophy caused by group VIA phospholipase A2 deficiency in mice: a model of human neurodegenerative disease | Q52585406 | ||
| Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio | Q53223116 | ||
| Patterns of levels of biological metals in CSF differ among neurodegenerative diseases. | Q53316529 | ||
| VPS29-VPS35 intermediate of retromer is stable and may be involved in the retromer complex assembly process | Q53520639 | ||
| Frequency of parkin mutations in late-onset Parkinson's disease | Q54314195 | ||
| ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome. | Q54532651 | ||
| A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. | Q54683068 | ||
| The role of pathogenic DJ-1 mutations in Parkinson's disease. | Q54757155 | ||
| A susceptibility gene for late-onset idiopathic Parkinson's disease | Q57309530 | ||
| Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease | Q57629146 | ||
| Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families | Q57629162 | ||
| Collaborative Analysis of α-Synuclein Gene Promoter Variability and Parkinson Disease | Q57977634 | ||
| Juvenile dystonia-parkinsonism and dementia caused by a novel ATP13A2 frameshift mutation | Q61782148 | ||
| Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism. | Q67242933 | ||
| Serum levels of zinc and copper in patients with Parkinson's disease | Q67970656 | ||
| Response to L-DOPA in multiple system atrophy | Q70669094 | ||
| Western Nebraska family (family D) with autosomal dominant parkinsonism | Q72649944 | ||
| Reversible monoubiquitination regulates the Parkinson disease-associated ubiquitin hydrolase UCH-L1 | Q79677642 | ||
| Identification of a novel conserved sorting motif required for retromer-mediated endosome-to-TGN retrieval | Q80558370 | ||
| Regulation of Intracellular Manganese Homeostasis by Kufor-Rakeb Syndrome-associated ATP13A2 Protein | Q34197130 | ||
| How much phenotypic variation can be attributed to parkin genotype? | Q34218728 | ||
| Defining at-risk populations for Parkinson's disease: lessons from ongoing studies | Q34234632 | ||
| Parkin genetics: one model for Parkinson's disease | Q34300017 | ||
| Mitochondrial quality control mediated by PINK1 and Parkin: links to parkinsonism. | Q34309906 | ||
| Genetic causes of Parkinson's disease: UCHL-1. | Q34329594 | ||
| G51D α‐synuclein mutation causes a novel Parkinsonian–pyramidal syndrome | Q34335126 | ||
| Analysis of the human VPS13 gene family | Q34361025 | ||
| Human DJ-1-specific Transcriptional Activation of Tyrosine Hydroxylase Gene | Q34400824 | ||
| Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives | Q34426072 | ||
| Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia | Q34429799 | ||
| DNAJC6 Mutations Associated With Early-Onset Parkinson's Disease. | Q34500305 | ||
| The genetic background of Parkinson's disease: current progress and future prospects | Q34513714 | ||
| PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron | Q34568479 | ||
| Characterization of PLA2G6 as a locus for dystonia-parkinsonism | Q34593410 | ||
| Phenotypic spectrum of patients with PLA2G6 mutation and PARK14 -linked parkinsonism | Q34624303 | ||
| Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial | Q34640765 | ||
| In vivo demonstration that alpha-synuclein oligomers are toxic | Q34652122 | ||
| A new look at James Parkinson's Essay on the Shaking Palsy | Q34657710 | ||
| Modulation of mitochondrial function and morphology by interaction of Omi/HtrA2 with the mitochondrial fusion factor OPA1. | Q34713631 | ||
| Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome | Q34726815 | ||
| Recent developments in adeno-associated virus vector technology | Q34775483 | ||
| The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization | Q34836156 | ||
| Phenotype, diagnosis, and treatment of Gaucher's disease | Q34907714 | ||
| Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease | Q34915213 | ||
| The Nrf2-ARE cytoprotective pathway in astrocytes | Q34984506 | ||
| Genome-wide association study confirms extant PD risk loci among the Dutch | Q35030975 | ||
| Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis | Q35058315 | ||
| VPS35 mutations in Parkinson disease | Q35103751 | ||
| Both ubiquitin ligases FBXW8 and PARK2 are sequestrated into insolubility by ATXN2 PolyQ expansions, but only FBXW8 expression is dysregulated | Q35196519 | ||
| Parkinsonism among Gaucher disease carriers | Q35444509 | ||
| Novel variant Pro143Ala in HTRA2 contributes to Parkinson's disease by inducing hyperphosphorylation of HTRA2 protein in mitochondria. | Q35544534 | ||
| CHCHD2 inhibits apoptosis by interacting with Bcl-x L to regulate Bax activation. | Q35579307 | ||
| The LRRK2 inhibitor GSK2578215A induces protective autophagy in SH-SY5Y cells: involvement of Drp-1-mediated mitochondrial fission and mitochondrial-derived ROS signaling. | Q35679501 | ||
| Role of PINK1 binding to the TOM complex and alternate intracellular membranes in recruitment and activation of the E3 ligase Parkin | Q35783335 | ||
| Deficiency of Calcium-Independent Phospholipase A2 Beta Induces Brain Iron Accumulation through Upregulation of Divalent Metal Transporter 1 | Q35823121 | ||
| Mitochondrial processing peptidase regulates PINK1 processing, import and Parkin recruitment | Q35874914 | ||
| Disruption of Protein Quality Control in Parkinson's Disease | Q35902695 | ||
| Gaucher disease: complexity in a "simple" disorder | Q35908938 | ||
| Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease | Q35914877 | ||
| Ubiquitin, proteasome and parkin | Q35967578 | ||
| Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. | Q36066469 | ||
| Analysis of neural subtypes reveals selective mitochondrial dysfunction in dopaminergic neurons from parkin mutants | Q36068874 | ||
| The PINK1-PARKIN Mitochondrial Ubiquitylation Pathway Drives a Program of OPTN/NDP52 Recruitment and TBK1 Activation to Promote Mitophagy | Q36118105 | ||
| OPA1 processing controls mitochondrial fusion and is regulated by mRNA splicing, membrane potential, and Yme1L. | Q36119045 | ||
| Amyloid precursor protein (APP) traffics from the cell surface via endosomes for amyloid β (Aβ) production in the trans -Golgi network | Q36132715 | ||
| Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A2 in activated cells | Q36182221 | ||
| The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies | Q36324942 | ||
| The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders | Q36486264 | ||
| Oxidized DJ-1 Inhibits p53 by Sequestering p53 from Promoters in a DNA-Binding Affinity-Dependent Manner | Q36559717 | ||
| Loss of HtrA2/Omi activity in non-neuronal tissues of adult mice causes premature aging | Q36560469 | ||
| The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease | Q36611426 | ||
| Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease | Q36622356 | ||
| The genetics of Parkinson's disease: Progress and therapeutic implications | Q36626825 | ||
| Processing of human cathepsin D is independent of its catalytic function and auto-activation: involvement of cathepsins L and B. | Q36646524 | ||
| Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays | Q36719174 | ||
| Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease | Q36785396 | ||
| Mitochondria on the move | Q36931216 | ||
| Moving mitochondria: establishing distribution of an essential organelle | Q36974920 | ||
| A multidisciplinary study of patients with early-onset PD with and without parkin mutations | Q37180446 | ||
| Tissue- and cell-specific mitochondrial defect in Parkin-deficient mice | Q27323332 | ||
| Structure of parkin reveals mechanisms for ubiquitin ligase activation | Q27684576 | ||
| Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 | ||
| alpha-Synuclein locus triplication causes Parkinson's disease | Q27860533 | ||
| Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors | Q27860937 | ||
| Parkinson's disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes α-Synuclein externalization via exosomes | Q27932080 | ||
| Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity | Q27934988 | ||
| Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance | Q28077356 | ||
| CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study | Q28114901 | ||
| Parkin and PINK1 function in a vesicular trafficking pathway regulating mitochondrial quality control | Q28114972 | ||
| GIGYF2 is present in endosomal compartments in the mammalian brains and enhances IGF-1-induced ERK1/2 activation | Q28116164 | ||
| ATP13A2 regulates mitochondrial bioenergetics through macroautophagy | Q28116275 | ||
| Inactivation of Omi/HtrA2 protease leads to the deregulation of mitochondrial Mulan E3 ubiquitin ligase and increased mitophagy | Q28116294 | ||
| Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase | Q28116395 | ||
| eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy | Q28118343 | ||
| ATP13A2 (PARK9) polymorphisms influence the neurotoxic effects of manganese | Q28118761 | ||
| Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice | Q28208193 | ||
| Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration | Q28237641 | ||
| Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease | Q28244731 | ||
| Translation initiator EIF4G1 mutations in familial Parkinson disease | Q28247679 | ||
| Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease | Q28257086 | ||
| The mitochondrial serine protease HtrA2/Omi: an overview | Q28263602 | ||
| Interaction between the Grb10 SH2 domain and the insulin receptor carboxyl terminus | Q28277690 | ||
| Evidence for the direct interaction of the insulin-like growth factor I receptor with IRS-1, Shc, and Grb10 | Q28287946 | ||
| The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein | Q28290750 | ||
| Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism | Q28293555 | ||
| Mapping of a gene for Parkinson's disease to chromosome 4q21-q23 | Q28295005 | ||
| FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome | Q28302099 | ||
| AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease | Q28304068 | ||
| A common LRRK2 mutation in idiopathic Parkinson's disease | Q28304886 | ||
| DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras | Q28305931 | ||
| Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model | Q28344741 | ||
| Truncated initiation factor eIF4G lacking an eIF4E binding site can support capped mRNA translation | Q28345095 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | genetic variation | Q349856 |
| neurodegeneration | Q1755122 | ||
| cell | Q7868 | ||
| mutation | Q42918 | ||
| Parkinson's disease | Q11085 | ||
| genetic predisposition to disease | Q64843122 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 1153-1178 | |
| P577 | publication date | 2018-04-26 | |
| 2018-08-01 | |||
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Cellular and Molecular Neurobiology | Q2333197 |
| P1476 | title | Parkinson Disease from Mendelian Forms to Genetic Susceptibility: New Molecular Insights into the Neurodegeneration Process | |
| P478 | volume | 38 |
| Q97519933 | Abnormal Mitochondrial Quality Control in Neurodegenerative Diseases |
| Q92632030 | Antioxidant Therapy in Parkinson's Disease: Insights from Drosophila melanogaster |
| Q92703211 | Case of Early-Onset Parkinson's Disease in a Heterozygous Mutation Carrier of the ATP7B Gene |
| Q60912710 | Circadian Rhythm Abnormalities in Parkinson's Disease from Humans to Flies and Back |
| Q89511106 | Copper Ions and Parkinson's Disease: Why Is Homeostasis So Relevant? |
| Q60915121 | Essential Tremor and Parkinson's Disease: Exploring the Relationship |
| Q64881100 | Evaluation of the frequency of non-motor symptoms of Parkinson's disease in adult patients with Gaucher disease type 1. |
| Q90637775 | Exosomes from Human Periapical Cyst-MSCs: Theranostic Application in Parkinson's Disease |
| Q90321601 | Functional and Neuroprotective Role of Striatal Adenosine A2A Receptor Heterotetramers |
| Q90745434 | Microbiota and Other Preventive Strategies and Non-genetic Risk Factors in Parkinson's Disease |
| Q90576886 | PF-06649751 efficacy and safety in early Parkinson's disease: a randomized, placebo-controlled trial |
| Q64904807 | Parkinson's Disease: Biomarkers, Treatment, and Risk Factors. |
| Q60923524 | Parkinson's disease and Alzheimer's disease: a Mendelian randomization study |
| Q99609968 | Post-GWAS knowledge gap: the how, where, and when |
| Q91635251 | Protein-Protein Interactions in Alpha-Synuclein Biogenesis: New Potential Targets in Parkinson's Disease |
| Q60921580 | Roco Proteins: GTPases with a Baroque Structure and Mechanism |
| Q61800082 | The Effects of rs894278 on Resting-State Brain Activity in Parkinson's Disease |
| Q92862300 | The Ras Superfamily of Small GTPases in Non-neoplastic Cerebral Diseases |
| Q57026122 | Using Patient-Derived Induced Pluripotent Stem Cells to Identify Parkinson's Disease-Relevant Phenotypes |
| Q92861469 | Vesicular Dysfunction and the Pathogenesis of Parkinson's Disease: Clues From Genetic Studies |
Search more.